Effect of toremifene on estrogen primed vaginal mucosa in postmenopausal women
- PMID: 2142237
- DOI: 10.1016/0022-4731(90)90009-h
Effect of toremifene on estrogen primed vaginal mucosa in postmenopausal women
Abstract
The antiestrogenic effect of 20 mg toremifene daily for 7 days and 68 mg for 5 days was studied in postmenopausal women volunteers primed for 7 days with estradiol valerate (2 mg daily orally) which was continued throughout the study. A control group received estrogen only and a reference group estrogen with 60 mg tamoxifen for 5 days. No treatment opposed the action of the estrogen on the endometrium but both 68 mg toremifene and 60 mg tamoxifen statistically significantly decreased the maturity index of vaginal cells on day 13. A decrease was also evident on day 18 with 20 mg toremifene.
Similar articles
-
Toremifene in postmenopausal breast cancer. Efficacy, safety and cost.Drugs Aging. 1997 Oct;11(4):261-70. doi: 10.2165/00002512-199711040-00002. Drugs Aging. 1997. PMID: 9342556 Review.
-
Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients.Breast Cancer Res Treat. 2003 Nov;82(2):103-11. doi: 10.1023/B:BREA.0000003957.54851.11. Breast Cancer Res Treat. 2003. PMID: 14692654 Clinical Trial.
-
Hormonal effects of toremifene in breast cancer patients.J Steroid Biochem. 1990 Jun 22;36(3):243-7. doi: 10.1016/0022-4731(90)90018-n. J Steroid Biochem. 1990. PMID: 2142246 Clinical Trial.
-
Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women.Maturitas. 2002 Nov 20;43(3):207-14. doi: 10.1016/s0378-5122(02)00206-2. Maturitas. 2002. PMID: 12443837 Clinical Trial.
-
[The anti-estrogenic effect of 4-chloro-1,2-diphenyl-1-(4-[2-(N,N-dimethylamino)ethoxy]phenyl)1-butene (Toremifene) on the endocrine regulation in breast cancer patients].Orv Hetil. 1991 Mar 31;132(13):683-6. Orv Hetil. 1991. PMID: 1826556 Review. Hungarian.
Cited by
-
Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer.Drugs. 1997 Jul;54(1):141-60. doi: 10.2165/00003495-199754010-00014. Drugs. 1997. PMID: 9211086 Review.
-
Toremifene in postmenopausal breast cancer. Efficacy, safety and cost.Drugs Aging. 1997 Oct;11(4):261-70. doi: 10.2165/00002512-199711040-00002. Drugs Aging. 1997. PMID: 9342556 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical